August 9, 2023

BSE Ltd.

Phiroze Jeejeebhoy Towers

Dalal Street

Mumbai 400 001

BSE Scrip Code : 506943

Stock Symbol: JBCHEPHARM

Dear Sir,

Sub: Company Presentation

Enclosed is Company's presentation on financial results for the quarter ended on June 30, 2023. The Company proposes to make/circulate this presentation to the investors/analysts.

Kindly take the same on record.

Thanking you,

Yours faithfully,

For J. B. Chemicals & Pharmaceuticals Limited

Sandeep

Anil

Phadnis

Digitally signed by Sandeep Anil Phadnis DN: c=IN, o=Personal, title=8434, pseudonym=108F69E4E868E4C1147674C1 3B2684AC9CDD8E36, 2.5.4.20=715f7603f235e5d1d74002aec03d2 4cf432efd8296e6e1c3c0c80534a90c098e, postalCode=411038, st=Maharashtra, serialNumber=CC500FDD638E71336FC58B 204E2BA05EA7C4ADE49B8FE438E8F254C3 00DEC735, cn=Sandeep Anil Phadnis Date: 2023.08.09 15:57:25 +05'30'

Sandeep Phadnis

Vice President - Secretarial

& Company Secretary

Encl: As above

JB Pharma - Q1 FY24

Investor Presentation

August 9, 2023

www.jbpharma.com

jbpharma/

Disclaimer

No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements" based on the currently held beliefs and assumptions of the management JB Chemicals & Pharmaceuticals Limited ("Company" or "JB Pharma" or "JB Chemicals & Pharmaceuticals Limited "), which are expressed in good faith and in their opinion reasonable, including those relating to the Company's general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatory environment.

Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company or industry results to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements, including future changes or developments in the Company's business, its competitive environment and political, economic, legal and social conditions. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements to reflect future events or developments.

This presentation is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation does not constitute an offer or invitation to purchase or subscribe for any securities in any jurisdiction, including the United States. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. None of our securities may be offered or sold in the United States, without registration under the U.S. Securities Act of 1933, as amended, or pursuant to an exemption from registration there from. This presentation is confidential and may not be copied or disseminated, in whole or in part, and in any manner.

2

46

Years of operations with consistent track record across multiple businesses

6

Brands among top 300 brands (IQVIA MAT Mar'23 data), contributing over 60% of domestic formulations revenues

40+

Regulated/semi-regulated markets of presence through direct operations and distributors

Top 5

Global manufacturer of medicated/herbal lozenges representing a substantial opportunity

26%

Growth in chronic therapies* in the domestic formulations business

2500+

Strong India field force# with therapy-focused segmentation

8

21%

Multi-dosage formulation

Strong ROCE** with

plants with key global

consistent cash flow

approvals/ compliances

generation

* CAGR over FY21-FY23 (IQVIA MAT Mar Nos)

#Includes MR and Supervisors

4

** ROCE for FY23 - ROCE = EBIT/(Net Worth + Net Debt - Mutual Fund Investments)

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

JB Chemicals & Pharmaceuticals Ltd. published this content on 09 August 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 August 2023 16:14:01 UTC.